Сравнительное исследование хромогранина А и хромогранина В у больных с нейроэндокринными опухолями желудка и поджелудочной железы
https://doi.org/10.17650/2313-805X-2021-8-3-8-13
Abstract
Introduction. Immunoenzyme assay of biochemical markers is one of the most important methods for examination of pa- tients with neuroendocrine tumors (NETs). Along with the generally accepted NET marker chromogranin A (CgA), another member of the granin family, chromogranin B (CgB), can serve as a complementary marker.
Objectives. Analysis of CgB as an additional to CgA biochemical marker in the blood serum of patients with gastric and pancreatic neuroendocrine tumors.
Materials and methods. We examined 79 patients with gastic (n = 14) and pancretic (n = 65) NETS, and 42 particularly healthy people, who were included in the control group. CgB and CgA were determined with ELISA method using the Human Chromogranin B (USCN, China) and Chromogranin A NEOLISA (Eurodiagnostica, Sweden) test systems.
,
Results. CgB levels in gastric and pancreatic NETs were significantly higher than in control group. CgB concentrations were independent of tumor spread and its biological activity. ROC analysis in common group of NETs relative to control group showed AUC for CgB = 0.869 and for CgA AUC = 0.82. According to results in common group of NET patients when used isolated, CgA and CgB have comparable diagnostic sensitivity, which increases in complex use to 82.5 %. In the group of NET patients with low levels of CgA (<100 ng/ml), an increase in CgB concentration above the cut-off level (>15.7 ng/ml) was observed in 53.6 % of cases.
Conclusion. The combination of CgB and CgA in gastric and pancreatic NETs could increase the diagnostic efficacy of bio- chemical diagnostics. The received data confirms the significance of CgB as a complementary biomarker of NETs.
About the Authors
N. V. Lyubimova
N.N. Blokhin National Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Yu. S. Timofeev
N.N. Blokhin National Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
A. V. Lebedeva
N.N. Blokhin National Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
N. E. Kushlinskii
N.N. Blokhin National Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
References
1. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011;18(1):17–25. DOI: 10.1530/ERC-10-0280.
2. Modlin I.M., Gustafsson B.I., Moss S.F. et al. Chromogranin A – biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 2010;17(9):2427–43. DOI: 10.1245/s10434-010-1006-3.
3. Aluri V., Dilon J.S. Biochemical testing in neuroendocrine tumors. Endocrinol Metab Clin North Am 2017;46(3):669–77. DOI: 10.1016/j.ecl.2017.04.004.
4. Vinik A.I., Silva M.P., Woltering E.A. et al. Biochemical testing for neuroendocrine tumors. Pancreas 2009;38(8):876–89. DOI: 10.1097/MPA.0b013e3181bc0e77.
5. Pulvirenti A., Rao D., Mcintyre C.A. et al. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford) 2019;21(5):612–8. DOI: 10.1016/j.hpb.2018.09.016.
6. Cheng Y., Sun Z., Bai C., Yan X. et al. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors. Tumour Biol 2016;37(3):2863–9. DOI: 10.1007/s13277-015-4114-7.
7. Jun E., Kim S.C., Song K.B. et al. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute. Surgery 2017;162(1):120–30. DOI: 10.1016/j.surg.2017.01.019.
8. Cheng Y., Sun Z., Bai C. et al. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors. Tumour Biol 2016;37(3):2863–9. DOI: 10.1007/s13277-015-4114-7.
9. Ma Z.Y., Gong Y.F., Zhuang H.K. et al. Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management. World J Gastroenterol 2020;26(19):2305–22. DOI: 10.3748/wjg.v26.i19.2305.
10. Lyubimova N.V., Churikova T.K., Kushlinsky N.E. Chromogranin A is a biochemical marker of neuroendocrine tumors. Byulleten’ eksperimental’noj biologii i mediciny = Bulletin of Experimental Biology and Medicine 2015;160(1):657–60. (In Russ.). DOI: 10.1007/s10517-016-3254-0.
11. Lyubimova N.V., Toms M.G., Churikova T.K., Haritidi T.Y. Clinical significance of chromogranin A in neuroendocrine tumors of the gastrointestinal tract. Al’manah klinicheskoj mediciny = Almanac of Clinical Medicine 2015;41:35–9. (In Russ.). DOI: 10.18786/2072-0505-2015-41-35-39.
12. Campana D., Nori F., Piscitelli L. et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007;25(15):1967–73. DOI: 10.1200/JCO.2006.10.1535.
13. Stridsberg M., Eriksson B., Fellstrom B. et al. Measurement of chromogranin B can serve as a complement to chromogranin A. Regulatory Peptides 2007;193:80–3. DOI: 10.1016/j.regpep.2006.10.008.
14. Stridsberg M., Oberg K., Li Q. et al. Measurment of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. Journal of endocrinology 1995;144(1):49–59. DOI: 10.1677/joe.0.1440049.
15. Miki M., Tetuhide I., Hijoka M. et al. Utility of chromogranin B as a biomarker in Japanese patients with pancreatic neuroendocrine tumors. Jpn J Clin Oncol 2017;47(6):520–8. DOI: 10.1093/jjco/hyx032.
16. Bech P.R., Martin N.M., Ramachandran R., Bloom S.R. The biochemical utility of chromogranin A, chromogranin B and cocaine – and amphetamine-regulated transcript for neuroendocrine neoplasia. Ann Clin Biochem 2014;51(1):8–21. DOI: 10.1177/0004563213489670.
17. Lyubimova N.V., Timofeev Yu.S., Lebedeva A.V., Kushlinsky N.E. Chromogranin A and chromogranin B in neuroendocrine tumors of the pancreas. Medicinskij alfavit = Medical Alphabet 2020;8:26–8. (In Russ.). DOI: 10.33667/2078-5631-2020-8-26-28.
Review
For citations:
Lyubimova N.V., Timofeev Yu.S., Lebedeva A.V., Kushlinskii N.E. . Advances in Molecular Oncology. 2021;8(3):8-13. (In Russ.) https://doi.org/10.17650/2313-805X-2021-8-3-8-13
Views:
548
Email this article 